ISA reports highlights of randomized Phase 2 cancer vaccine trial in head & neck cancer

ISA to Present at the 4th Annual Virtual H.C. Wainwright HBV Conference on October 25th

First Patient with Chronic Hepatitis B Dosed with ISA104 in First-in-Human Phase 1 Study

The combination of ISA101b and Libtayo® shows promising results in patients whose head and neck cancer progressed on anti-PD1 therapy

ISA to Present First Clinical Trial Data from the Phase II Study of ISA101b and Libtayo® (cemiplimab) Combination in Head and Neck Cancer at the ASCO Annual Meeting 2023

ISA to Present Pre-clinical Data on its Protective SLP Therapy Against SARS-CoV-2 at the CIMT Annual Meeting

ISA Pharmaceuticals to Attend and Present at Upcoming Scientific and Business Conferences

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma